Replies to post #232729 on Biotech Values

[DewDiligence]

The phase-1 trial of EID-2801 has three parts. The first two (non-randomized) parts of the trial have evidently been completed.

[DewDiligence]

EIDD-2801 begins phase-2 in COVID-19:

https://www.businesswire.com/news/home/20200619005038/en

This program is now being run by MRK.

[DewDiligence]

MRK/Ridgeback report_preliminary_data_on_oral_COVID_antiviral, Molnupiravir:

https://finance.yahoo.com/news/ridgeback-biotherapeutics-merck-announce-preliminary-050100984.html

This multi-center U.S. Phase 2a study enrolled 202 non-hospitalized adults who had signs or symptoms of COVID-19 within 7 days and confirmed active SARS-CoV-2 infection. The primary efficacy objective was reduction in time to viral negativity measured by reverse transcriptase polymerase chain reaction (RT-PCR) analysis of nasopharyngeal swabs… Of the 182 participants with an evaluable nasopharyngeal swab, 42% (78/182) showed detectable levels of cultured virus at baseline. The full study results remain blinded and will be shared at a later date, as they become available.

…Today’s presentation described findings from the secondary endpoint of reduction in time (days) to negativity of infectious virus isolation in nasopharyngeal swabs from participants with symptomatic SARS-CoV-2 infection, as determined by isolation in Vero cell line culture [i.e. not via PCR]. At day 5, there was a reduction…in positive viral culture in subjects who received molnupiravir (all doses) compared to placebo: 0% (0/47) for molnupiravir and 24% (6/25) for placebo.